It has been more than three years since Moderna's mRNA technology proved it could protect against a respiratory virus in the real world. Today, that platform faces a new and historic test: the first-ever FDA advisory committee vote on an mRNA-based seasonal influenza vaccine.
The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) convened June 18, 2026, to assess the benefit-risk profile of MFLUSIVA (mRNA-1010), Moderna's investigational trivalent mRNA seasonal influenza vaccine, with the FDA's formal decision date set for August 5, 2026. The pre-meeting briefing documents released June 16 showed no "major deficiencies," triggering a 9% stock surge and setting up what may be a landmark moment in vaccine history.
